Claims for Patent: 6,699,833

Summary for Patent: 6,699,833

Title:	Pharmaceutical formulations for sustained drug delivery
Abstract:	Sustained delivery formulations comprising a water-insoluble complex of a peptide and a carrier macromolecule are disclosed. The formulations of the invention allow for loading of high concentrations of peptide in a small volume and for delivery of a pharmaceutically active peptide for prolonged periods, e.g., one month, after administration of the complex. The complexes of the invention can be milled or crushed to a fine powder. In powdered form, the complexes form stable aqueous suspensions and dispersions, suitable for injection. In a preferred embodiment, the peptide of the complex is an LHRH analogue, preferably an LHRH antagonist, and the carrier macromolecule is an anionic polymer, preferably carboxymethylcellulose. Methods of making the complexes of the invention, and methods of using LHRH-analogue-containing complexes to treat conditions treatable with an LHRH analogue, are also disclosed.
Inventor(s):	Gefter; Malcolm L. (Lincoln, MA), Barker; Nicholas (Southborough, MA), Musso; Gary (Hopkinton, MA), Molineaux; Christopher J. (Brookline, CA)
Assignee:	Praecis Pharmaceuticals, Inc. (Cambridge, MA)
Application Number:	09/349,914
Patent Claims:	1. A pharmaceutical composition comprising a solid ionic complex of a pharmaceutically active peptide and a carrier macromolecule, wherein the peptide content of said complex is at least 57% by weight. 2. A pharmaceutical composition consisting essentially of a solid ionic complex of a pharmaceutically active peptide and a carrier macromolecule, wherein the peptide content of said complex is at least 57% by weight. 3. The pharmaceutical composition of any one of claim 1 or 2, wherein said pharmaceutically active peptide is an LHRH analogue. 4. The pharmaceutical composition of claim 3 wherein said pharmaceutically active peptide is an LHRH antagonist. 5. The pharmaceutical composition of any one of claim 1 or 2, wherein said pharmaceutically active peptide is selected from the group consisting of bradykinin analogues, parathyroid hormone, adenocorticotrophic hormone, calcitonin, and vasopressin analogues. 6. The pharmaceutical composition of any one of claim 1 or 2, wherein the pharmaceutically active peptide is cationic and the carrier macromolecule is anionic. 7. The pharmaceutical composition of any one of claim 1 or 2, wherein the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least one week after the pharmaceutical composition is administered to the subject. 8. The pharmaceutical composition of any one of claim 1 or 2, wherein the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least two weeks after the pharmaceutical composition is administered to the subject. 9. The pharmaceutical composition of any one of claim 1 or 2, wherein the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least three weeks after the pharmaceutical composition is administered to the subject. 10. The pharmaceutical composition of any one of claim 1 or 2, wherein the complex provides sustained delivery of the pharmaceutically active peptide to a subject for at least four weeks after the pharmaceutical composition is administered to the subject. 11. The pharmaceutical composition of any one of claim 1 or 2, wherein the pharmaceutically active peptide is a multivalent cationic or anionic peptide. 12. The pharmaceutical composition of any one of claim 1 or 2, wherein the peptide is 5 to 20 amino acids in length. 13. The pharmaceutical composition of any one of claim 1 or 2, wherein the peptide is 8 to 15 amino acids in length. 14. The pharmaceutical composition of any one of claim 1 or 2, wherein the peptide is 8 to 12 amino acids in length. 15. The pharmaceutical composition of any one of claim 1 or 2, wherein the carrier macromolecule is an anionic polymer. 16. The pharmaceutical composition of any one of claim 1 or 2, wherein the carrier macromolecule is an anionic polyalcohol. 17. The pharmaceutical composition of any one of claim 1 or 2, wherein the carrier macromolecule is an anionic polysaccharide. 18. The pharmaceutical composition of any one of claim 1 or 2, wherein the carrier macromolecule is carboxymethylcellulose. 19. The pharmaceutical composition of any one of claim 1 or 2, wherein the carrier macromolecule is selected from the group consisting of algin, alginate, anionic acetate polymers, anionic acrylic polymers, xantham gums, anionic carageenan, anionic polygalacturonic acid, sodium starch glycolate, and pharmaceutically acceptable salts thereof. 20. The pharmaceutical composition of any one of claim 1 or 2, which is a lyophilized solid. 21. The pharmaceutical composition of any one of claim 1 or 2, wherein said solid ionic complex is suspended as a liquid suspension or dispersed as a semi-solid dispersion. 22. The pharmaceutical composition of claim 3 wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a D-asparagine structure. 23. The pharmaceutical composition of claim 3 wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound comprising a structure: wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal B is His or 4-Cl-D-Phe C is Trp, D-Pal, D-Nal, L-Nal, D-Pal(N-O), or D-Trp D is Ser E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile; F is D-Asn, D-Gln, or D-Thr; G is Leu or Trp; H is Lys(iPr), Gln, Met, or Arg I is Pro; and J is Gly-NH.sub.2 or D-Ala-NH.sub.2 ; or a pharmaceutically acceptable salt thereof. 24. A pharmaceutical composition comprising a solid ionic complex of an LHRH analogue and a carrier macromolecule, wherein the LHRH analogue content of said complex is at least 57% by weight. 25. A pharmaceutical composition consisting essentially of a solid ionic complex of an LHRH analogue and a carrier macromolecule, wherein the LHRH analogue content of said complex is at least 57% by weight. 26. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is an LHRH antagonist having the following structure: Ac-D-Nal-4-Cl-D-Phe-D-Pal-Ser-N-Me-Tyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala. 27. The pharmaceutical composition of any one of claim 24 or 25, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least one week after the pharmaceutical composition is administered to the subject. 28. The pharmaceutical composition of any one of claim 24 or 25, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least two weeks after the pharmaceutical composition is administered to the subject. 29. The pharmaceutical composition of any one of claim 24 or 25, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least three weeks after the pharmaceutical composition is administered to the subject. 30. The pharmaceutical composition of any one of claim 24 or 25, wherein the complex provides sustained delivery of the LHRH analogue to a subject for at least four weeks after the pharmaceutical composition is administered to the subject. 31. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is a multivalent cationic or anionic peptide. 32. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is 5 to 20 amino acids in length. 33. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is 8 to 15 amino acids in length. 34. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is 8 to 12 amino acids in length. 35. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound, wherein a residue of the peptide compound corresponding to the amino acid at position 6 of natural mammalian LHRH comprises a D-asparagine structure. 36. The pharmaceutical composition of any one of claim 24 or 25, wherein the LHRH analogue is an LHRH antagonist comprising a peptide compound comprising a structure: wherein A is pyro-Glu, Ac-D-Nal, Ac-D-Qal, Ac-Sar, or Ac-D-Pal B is His or 4-Cl-D-Phe C is Trp, D-Pal, D-Nal, L-Nal, D-Pal(N-O), or D-Trp D is Ser E is N-Me-Ala, Tyr, N-Me-Tyr, Ser, Lys(iPr), 4-Cl-Phe, His, Asn, Met, Ala, Arg or Ile; F is D-Asn, D-Gln, or D-Thr; G is Leu or Trp; H is Lys(iPr), Gln, Met, or Arg I is Pro; and J is Gly-NH.sub.2 or D-Ala-NH.sub.2 ; or a pharmaceutically acceptable salt thereof.